Deutsche Bank AG Buys 13,995 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Deutsche Bank AG increased its stake in Bristol Myers Squibb by 0.1% in Q1, holding approximately 9.58 million shares valued at $584.31 million.
• Bristol Myers Squibb reported a Q2 EPS of $1.46, exceeding expectations, with quarterly revenue reaching $12.27 billion.
• The company declared a quarterly dividend of $0.62, resulting in an annual yield of 5.5%, with a current dividend payout ratio of 100%.

Deutsche Bank AG raised its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,580,456 shares of the biopharmaceutical company's stock after buying an additional 13,995 shares during the quarter. Deutsche Bank AG owned 0.47% of Bristol Myers Squibb worth $584,312,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of Bristol Myers Squibb by 0.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 60,606,905 shares of the biopharmaceutical company's stock worth $3,696,415,000 after acquiring an additional 306,430 shares in the last quarter. ASR Vermogensbeheer N.V. bought a new position in Bristol Myers Squibb in the first quarter valued at approximately $14,413,000. Citizens Financial Group Inc. RI grew its stake in Bristol Myers Squibb by 18.0% in the first quarter. Citizens Financial Group Inc. RI now owns 35,337 shares of the biopharmaceutical company's stock valued at $2,155,000 after purchasing an additional 5,395 shares in the last quarter. Greykasell Wealth Strategies Inc. bought a new position in Bristol Myers Squibb in the first quarter valued at approximately $117,000. Finally, Primecap Management Co. CA grew its stake in Bristol Myers Squibb by 0.9% in the first quarter. Primecap Management Co. CA now owns 22,970,633 shares of the biopharmaceutical company's stock valued at $1,400,979,000 after purchasing an additional 197,453 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Piper Sandler started coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target for the company. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. UBS Group cut their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Finally, William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and a consensus target price of $56.38.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock traded up $0.60 during trading on Friday, reaching $45.96. 9,987,114 shares of the company's stock were exchanged, compared to its average volume of 13,753,402. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The company has a market cap of $93.55 billion, a P/E ratio of 18.53, a PEG ratio of 2.32 and a beta of 0.36. The firm's 50-day moving average price is $47.32 and its 200 day moving average price is $51.90.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. Bristol Myers Squibb's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.07 EPS. As a group, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a dividend of $0.62 per share. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.4%. Bristol Myers Squibb's payout ratio is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.